Janssen Nearing Application For Japanese Approval Of Razadyne
This article was originally published in PharmAsia News
Executive Summary
Janssen Pharmaceutical KK of Japan says its Phase III trial of an Alzheimer's disease drug has moved to the point it plans to apply for marketing approval in Japan next year. Razadyne (galantamine hydrobromide) by Janssen's parent, Johnson & Johnson, already is marketed in more than 50 countries for inhibiting cholinesterase and modulating nicotinic receptors in the brain to promote synthesis of acetylcholine. Razadyne would compete in the Japanese market against Eisai's Aricept (donepezil hydrochloride). (Click here for more - prescription may be required